ClinicalTrials.gg
CompletedNCT02069093Updated Feb 13, 2017Results posted

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

A Phase 2 interventional study of Dexamethasone based mouthwash and Everolimus in Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.

Enrollment
32nd of 78
92 · median 55
Started
2014
with 13 others
Phase 2
40 of 78
3 open now
Registered
48th of 78
by date
Lead sponsor
14 of 78
Novartis Pharmaceuticals

Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 32nd largest by enrollment, is one of 14 that started in 2014, is one of 40 in phase 2, and was the 48th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing everolimus in Breast Neoplasms, or all of them as a file.
02

Study summary

Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult women > 18 years of age with or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy
  2. Histological or cytological confirmation of hormone-receptor positive (HR+) human epidermal growth factor receptor 2 negative (-) breast cancer
  3. women. Postmenopausal status is defined either by:

    • Age ≥ 55 years and one year or more of amenorrhea
    • Age \< 55 years and one year or more of amenorrhea, with an estradiol assay \< 20 pg/ml
    • Surgical menopause with bilateral oophorectomy
    • Note: Ovarian radiation or treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression
  4. Patient has been assessed by treating physician to be appropriate candidate for everolimus plus exemestane therapy as treatment of advanced or metastatic breast cancer and plans to prescribe everolimus 10mg PO QD in combination with exemestane 25mg PO QD
  5. Patient must start everolimus 10mg plus exemestane 25mg treatment on Cycle 1 Day 1 of trial
  6. Performance status ≤ 2
  7. Adequate renal function: serum creatinine ≤ 1.5x ;
  8. Willingness to self-report level of oral pain using Visual Analog Scale (VAS) and the Normalcy Diet Scale (NDS) throughout each stomatitis event, as required in the patient diary. At baseline, patient's self-reported oral pain level, using VAS, must be 0 and the normalcy diet scale score should ≥ 60
  9. Signed obtained prior to any screening procedure

Exclusion criteria

Exclusion criteria:

  1. Patients currently receiving anticancer therapies (except biphosphonate, denosumab);
  2. Patients who currently have stomatitis/oral mucositis/mouth ulcers;
  3. Known intolerance or to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);
  4. Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral Everolimus;
  5. Uncontrolled diabetes mellitus as defined by >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary;
  6. Patients who have any severe and/or uncontrolled medical conditions such as:

    • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other cardiac disease
    • Symptomatic congestive heart failure of Class III or IV
    • active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease (except for Hep B and Hep C positive patients)
    • Known severely impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air)
    • active, bleeding diathesis;
  7. Chronic treatment with or other agents. Topical or inhaled corticosteroids are allowed;
  8. Known history of seropositivity;
  9. Patients who have received within 1 week of start of everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;
  10. Patients who have a history of another primary , with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for ≥3 years;
  11. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study or patient diaries;
  12. Patients who are currently part of any clinical investigation or who has not had resolution of all acute toxic effects or prior anti-cancer therapy to version 4.03 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Dexamethasone based mouthwash

    Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.

    Drug: Dexamethasone based mouthwash · Drug: Everolimus · Drug: Exemestane

Interventions

  • DrugDexamethasone based mouthwash

    Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.

  • Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.

  • Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Stomatitis Grade ≥ 2

    The incidence of grade ≥ 2 stomatitis was reported. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.

    Time frame: 56 days

Secondary outcomes

  1. Time to Resolution of Stomatitis From Grade 2 or Greater to Grade 1 or Less

    The number of days to achieve resolution of stomatitis from grade 2 or greater to grade 1 or less was assessed. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.

    Time frame: 56 days

  2. Median Number of Mouthwashes Per Day

    The median number of mouthwashes per day was assessed.

    Time frame: 56 days

  3. Number of Participants With All Grades of Stomatitis

    The number of participants with all grades of stomatitis was defined as the number of participants who had stomatitis grade 1 or higher. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.

    Time frame: 56 days

  4. Dose Intensity of Everolimus and Exemestane

    The dose intensity was calculated as the cumulative dose of everolimus or exemestane divided by the length of time on treatment during the first 56 days of treatment.

    Time frame: 56 days

  5. Blood Concentration of Everolimus and Exemestane

    Blood samples were collected and analyzed.

    Time frame: 28 days (pre-dose)

07

Results

Posted Feb 13, 2017

Participant flow

Participant flow — Overall Study
MilestoneDexamethasone Based Mouthwash
Started86
Pharmacokinetic analysis set50
Completed56
Not completed30
Withdrew: Disease progression14
Withdrew: New cancer therapy1
Withdrew: Death1
Withdrew: Administrative problems1
Withdrew: Withdrawal by subject2
Withdrew: Abnormal laboratory values1
Withdrew: Adverse event10

Outcome measures

PrimaryNumber of Participants With Stomatitis Grade ≥ 2

The incidence of grade ≥ 2 stomatitis was reported. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.

Time frame:
56 days
Reported as:
Number · Participants
Number of Participants With Stomatitis Grade ≥ 2
ParticipantsDexamethasone Based Mouthwash
Stomatitis grade >=2: Yes2
Stomatitis grade >=2: No83
Stomatitis grade >=2: Not evaluable1
Statistical analysis
  • Dexamethasone Based Mouthwash · Incidence rate R · p = <0.001
SecondaryTime to Resolution of Stomatitis From Grade 2 or Greater to Grade 1 or Less

The number of days to achieve resolution of stomatitis from grade 2 or greater to grade 1 or less was assessed. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.

Time frame:
56 days
Reported as:
Median · Days
Time to Resolution of Stomatitis From Grade 2 or Greater to Grade 1 or Less
DaysDexamethasone Based Mouthwash
Time to Resolution of Stomatitis From Grade 2 or Greater to Grade 1 or LessNA (NA to NA)
SecondaryMedian Number of Mouthwashes Per Day

The median number of mouthwashes per day was assessed.

Time frame:
56 days
Reported as:
Median · Number of mouthwashes
Median Number of Mouthwashes Per Day
Number of mouthwashesDexamethasone Based Mouthwash
Median Number of Mouthwashes Per Day3.95 (1.9 to 4.0)
SecondaryNumber of Participants With All Grades of Stomatitis

The number of participants with all grades of stomatitis was defined as the number of participants who had stomatitis grade 1 or higher. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences.

Time frame:
56 days
Reported as:
Number · Participants
Number of Participants With All Grades of Stomatitis
ParticipantsDexamethasone Based Mouthwash
Stomatitis all grade18
Not evaluable1
SecondaryDose Intensity of Everolimus and Exemestane

The dose intensity was calculated as the cumulative dose of everolimus or exemestane divided by the length of time on treatment during the first 56 days of treatment.

Time frame:
56 days
Reported as:
Median · mg/day
Dose Intensity of Everolimus and Exemestane
mg/dayDexamethasone Based Mouthwash
Everolimus10.0 (3 to 10)
Exemestane25.0 (8 to 25)
SecondaryBlood Concentration of Everolimus and Exemestane

Blood samples were collected and analyzed.

Time frame:
28 days (pre-dose)
Reported as:
Geometric mean · ng/mL
Blood Concentration of Everolimus and Exemestane
ng/mLDexamethasone Based Mouthwash
Everolimus (n=42)12.047 ± 56.492
Exemestane (n=48)0.657 ± 234.578

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexamethasone Based Mouthwash—20/92 (21.7%)72/92 (78.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDexamethasone Based Mouthwash
DyspnoeaRespiratory, thoracic and mediastinal disorders3/92
PyrexiaGeneral disorders2/92
PneumoniaInfections and infestations2/92
Acute kidney injuryRenal and urinary disorders2/92
Respiratory failureRespiratory, thoracic and mediastinal disorders2/92
LymphadenopathyBlood and lymphatic system disorders1/92
Cardiac failureCardiac disorders1/92
Pericardial effusionCardiac disorders1/92
Gastric ulcerGastrointestinal disorders1/92
Rectal haemorrhageGastrointestinal disorders1/92
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDexamethasone Based Mouthwash
StomatitisGastrointestinal disorders25/92
FatigueGeneral disorders16/92
NauseaGastrointestinal disorders14/92
HyperglycaemiaMetabolism and nutrition disorders14/92
DysgeusiaNervous system disorders12/92
DyspnoeaRespiratory, thoracic and mediastinal disorders11/92
DiarrhoeaGastrointestinal disorders10/92
HeadacheNervous system disorders10/92
CoughRespiratory, thoracic and mediastinal disorders10/92
InsomniaPsychiatric disorders9/92

Baseline characteristics

Full analysis set: The full analysis set consisted of all participants who received at least one dose of study treatment (everolimus and/or exemestane) and at least one dose of investigational treatment (dexamethasone mouth wash).

Age, Continuous
Age, Continuous(Years)Dexamethasone Based Mouthwash
Mean61.02 ± 10.921
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Dexamethasone Based Mouthwash
Female86
08

Study locations

23 sites
  • Highlands Oncology Group Highlands Oncology Group (22)
    Fayetteville, Arkansas 72703, United States
  • Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C
    Anaheim, California 92807, United States
  • Los Angeles Hematology/Oncology Medical Group
    Los Angeles, California 90017, United States
  • University of California at Los Angeles UCLA and TRIO Network
    Los Angeles, California 90095-6956, United States
  • University of California Irvine UC Irvine Medical Center
    Orange, California 92868, United States
  • University of California San Francisco UCSF Medical Center
    San Francisco, California 94101, United States
  • California Pacific Medical Center SC
    San Francisco, California 94115, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030-3940, United States
  • Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
  • OnCare Hawaii
    Aiea, Hawaii 96701, United States
  • North Shore University Health System NorthShore University
    Evanston, Illinois 60201, United States
  • Oncology Specialists, SC Onc Specialists
    Park Ridge, Illinois 60068-0736, United States
  • University of Maryland School of Medicine University of Maryland
    Baltimore, Maryland 21201-1559, United States
  • Kaiser Permanente - Mid Atlantic Permanete Research Institut Kaiser Permanente Mid-Atlantic
    Rockville, Maryland 20850, United States
  • Karmanos Cancer Institute Karmanos Cancer Institute (2)
    Detroit, Michigan 48201, United States
  • Saint Luke's Hospital/Marion Bloch Neuroscience Institute Cancer Institute
    Kansas City, Missouri 64111, United States
  • Regional Cancer Care Associates Cancer and Hematologic Disease
    Cherry Hill, New Jersey 08003, United States
  • Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2)
    Morristown, New Jersey 07962, United States
  • M. Francisco Gonzalez, MD.PA Hematology Oncology Center
    Columbia, South Carolina 29203, United States
  • Oncology Consultants Oncology Consultants, P.A.
    Houston, Texas 77024, United States
  • University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(2)
    Houston, Texas 77030-4009, United States
  • Delta Oncology Associates Delta Hematology/Oncology
    Portsmouth, Virginia 23704, United States
  • Northwest Medical Specialties Northwest Medical - Puyallup
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. Oncologist. 2020 Feb;25(2):e223-e230. doi: 10.1634/theoncologist.2019-0382. Epub 2019 Oct 8. PubMed 32043762 ↗
  • Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. Oncologist. 2019 Oct 8:theoncologist.2019-0382. doi: 10.1634/theoncologist.2019-0382. Online ahead of print. PubMed 31594912 ↗
  • Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 May;18(5):654-662. doi: 10.1016/S1470-2045(17)30109-2. Epub 2017 Mar 15. PubMed 28314691 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2014
First posted
Feb 21, 2014
Start
May 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Feb 13, 2017
Last update
Feb 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02069093
Responsible party
Sponsor
First posted
Feb 21, 2014
Start date
May 2014
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Feb 13, 2017
Last update
Feb 13, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion